Haoda Fu

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

Gregory Gaich, Jenny Y. Chien, Haoda Fu et al. · Cell Metabolism · 2013 · 867 citations · Full text

Obesity, Metabolic Syndrome, Health Sciences +10

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

Kyongsun Pak, Hajime Uno, Dae Hyun Kim et al. · JAMA Oncology · 2017 · 251 citations · Full text

Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies

Hajime Uno, Janet Wittes, Haoda Fu et al. · Annals of Internal Medicine · 2015 · 211 citations · Full text

Retrospective Cohort Study, Noninferiority Study, Noninferiority Studies +14

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Christof Kazda, Ying Ding, Ronan P. Kelly et al. · Diabetes Care · 2015 · 210 citations · Full text

Short‐term administration of the glucagon receptor antagonist <scp>LY2409021</scp> lowers blood glucose in healthy people and in those with type 2 diabetes

Raymond P. Kelly, Parag Garhyan, Eyas Raddad et al. · Diabetes Obesity and Metabolism · 2015 · 107 citations